Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQJB | ISIN: US52886N4060 | Ticker-Symbol:
NASDAQ
05.06.25 | 21:59
0,990 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
LEXARIA BIOSCIENCE CORP Chart 1 Jahr
5-Tage-Chart
LEXARIA BIOSCIENCE CORP 5-Tage-Chart

Aktuelle News zur LEXARIA BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoLexaria Bioscience Corp.: Lexaria Attending BIO International Convention156Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator...
► Artikel lesen
12.05.Lexaria advances drug delivery tech with PharmaCO2
LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln
12.05.Lexaria Bioscience Corp.: Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company828KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate...
► Artikel lesen
28.04.Lexaria Bioscience Corp. - 8-K, Current Report2
28.04.Lexaria Bioscience Corp.: Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock283KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the...
► Artikel lesen
25.04.Lexaria Bioscience announces $2M registered direct offering; shares slip 19%4
25.04.Pre-market Movers: Odyssey Marine Exploration, SES AI, VYNE Therapeutics, The OLB Group, Lexaria Bioscience626OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.30 A.M. ET).In the Green Odyssey Marine Exploration, Inc. (OMEX) is up over...
► Artikel lesen
25.04.Lexaria Bioscience secures $2 million in direct offering3
25.04.Lexaria Bioscience sichert sich 2 Millionen US-Dollar durch Direktplatzierung5
25.04.Lexaria Bioscience Corp.: Lexaria Announces $2 Million Registered Direct Offering of Common Stock262KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that...
► Artikel lesen
23.04.Lexaria Bioscience Corp.: Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology287Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23,...
► Artikel lesen
14.04.Lexaria Bioscience Corp. - 10-Q, Quarterly Report2
03.04.Lexaria schließt Patientenrekrutierung für Diabetes-Medikamentenstudie ab7
03.04.Lexaria completes enrollment for diabetes drug study2
03.04.Lexaria Bioscience Corp.: Lexaria Updates its Ongoing Human Study GLP-1-H24-4262Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria")...
► Artikel lesen
02.04.Lexaria begins human trial for oral diabetes treatment4
02.04.Lexaria Bioscience Corp.: Lexaria's Human GLP-1 Study #5 Begins Dosing286Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutideStudy will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April...
► Artikel lesen
18.03.Lexaria Bioscience Corp.: Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound4
18.03.Orale Tirzepatid-Kapseln erreichen gleiche Wirksamkeit wie Injektionen in Lexaria-Studie2
18.03.Oral tirzepatide capsules match injection efficacy in Lexaria study1
Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1